Phenosense Entry HIV Drug Resistance Assay
The Human Immunodeficiency virus type-1 (HIV-1) is a retrovirus that causes HIV disease and AIDS. Worldwide, there are over 33 million people infected. In the US, the Centers for Disease Control and Prevention (CDC) estimates that there are over a million HIV infected individuals, with one in five not knowing they are infected. Approximately 18,000 individuals die from HIV-related illnesses in the US each year.
HIV infects and destroys a specific type of white blood cell (WBC) called CD4 lymphocyte cells that are a major part of the body’s immune system. It is the subsequent depletion of these cells that results in the immune system becoming compromised, thus the term “immunocompromised.” Once the immune system is compromised, the body is susceptible to infections. Thus the goal of HIV therapy is to keep the level of circulating virus low and the level of CD4 cells high. There is currently no cure for infection with HIV; however, anti-retroviral drugs are available that are able to suppress viral replication, keeping the disease from progressing.
Currently, there are 4 classes of anti-retroviral drugs: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors. For most individuals, these drugs prove effective long-term in keeping HIV at bay. In some patients, however, mutations arise in HIV, making the drugs no longer effective. The mutations may be single nucleotide changes, or more commonly a series of mutations that will quickly render ineffective all the drugs in an entire class. Identifying the mutations early allows the physician to change medication before the virus rebounds.
Testing for HIV resistance can be done by two different methods. The first method involves identifying mutations in individual nucleotides in selected genes within the HIV genome. Different technologies are used to accomplish this, most notably DNA sequencing. Since HIV is an RNA virus, it is first reverse transcribed into DNA, which is subsequently sequenced. The resulting sequence is then compared to a database of sequences. The results then are used to predict whether the HIV in question is sensitive to the drug, resistant to the drug, or likely to become resistant in the future. This method is known as determining the HIV genotype.
The second method involves growing HIV in culture, adding it to different dilutions of the drug, and determining the concentration of the drug that is lethal, with the premise that resistant strains are able to grow in higher concentrations of the drug than susceptible strains. This method is known as determining an HIV phenotype.
- HIV therapy selection
- HIV treatment management
- HIV disease management
Positive in:
- HIV-1 infection with drug resistance
- Genotyping will report drug resistance based on known mutations, resistance is reported per drug or substance
- Phenotyping will report resistance per tested drug. Results are quantitative (IC50 ratio) as well as resistance interpretation (resistant or susceptible)
Negative (No HIV viral nucleic acid detected)
Plasma Citrate (Light Blue) or EDTA (Lavender).
Spin and separate plasma and freeze.
Stability
- Ambient: Unacceptable
- Refrigerated: 4 days
- Frozen: 60 days
2-4 weeks.
- BMC Bioinformatics. 2011 Dec 15;12(1):477. [PMID: 22172090]
- Ann Clin Lab Sci. 2002;32:406. [PMID: 12458895]
- J Infect Dis. 2006;194 (Suppl 1):S59. [PMID: 16921474]
- Mol Diagn. 2000 Sep;5(3):159-68. [PMID: 11070150]
- Curr Opin HIV AIDS. 2009 Nov;4(6):474-80. [PMID: 20048713]
- Med Res Rev. 2004 Jan;24(1):115-25. [PMID: 14595674]
- Clin Lab Med. 2002 Sep;22(3):637-49. [PMID: 1224459]